BullFrog AI Holdings is an investor-backed company determined to become the undisputed leader in precision medicine. Our mission is to find the link between therapies and patients, and improve their lives. Using our proprietary technology platform, we aim to predict which patients will benefit from which medications, effectively improving clinical outcomes and eliminating the problem of trial-and-error prescriptions.

We have an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors determined to help BullFrog AI Holdings revolutionize drug development. Through our partnership with one of the most prestigious research institutions in the world, we take pride in technology innovation by staying on the cutting edge of AI.

BullFrog AI Holdings Leadership

Vin Singh

Founder, CEO and Chairman

Mr. Singh is a dynamic visionary and experienced professional executive from the life sciences industry. He has extensive start-up experience having founded and built several companies in the life science space including BullFrog, Next Healthcare Inc., and MaxCyte Inc. Most recently, he led ThermoFisher Scientific’s global cell therapy services business. Vin has a BS in Electrical Engineering from Rutgers University, and MS in Biomedical Engineering from Rensselaer Polytechnic Institute, and an MBA from Johns Hopkins University. He is known for his strategic thinking, vision, and integrity.

BullFrog AI Advisors

Kristin Bigos

Dr. Kristin Bigos is an Assistant Professor of Medicine, Psychiatry, and Pharmacology at the Johns Hopkins University School of Medicine. Her research focuses on neuropsychiatric drug development and a precision medicine approach to the treatment of mental illness.

The Bigos Lab uses functional MRI as a biomarker to test the neural effects of drugs designed to treat symptoms of mental illness. Her lab currently has a pharmacoMRI study to develop a treatment for cognitive dysfunction in schizophrenia. Other studies aim to identify patient-specific variables including sex, race, and genetics that impact drug clearance and clinical response to better select and dose antipsychotics and antidepressants.

Dr. Bigos received her B.S. in Premedicine from the Pennsylvania State University. She earned her Ph.D. in Clinical Pharmaceutical Sciences from the University of Pittsburgh. She completed a post-doctoral fellowship in the Clinical Brain Disorders Branch of the Intramural Research Program of the National Institute of Mental Health under Dr. Daniel Weinberger. Before joining Johns Hopkins, she worked as an Investigator at the Lieber Institute for Brain Development.

Eric J. Roos

Eric Roos has more than 30 years of experience in the development of biopharmaceuticals, cell therapy and tissue engineered products. He maintained a variety of responsibilities in the cell therapy industry supporting early phase development, process optimization, and clinical trial execution. His early controlled release, formulation, and biomaterials experience in transdermal, cytokine stimulated wound healing, and environmentally responsive hydrogels were leveraged to develop the encapsulated cell therapy and neural stem cell programs at CytoTherapeutics. His cell therapy experiences were then applied to develop commercial tissue engineering process technologies for wound healing products as leader of Process Development at Organogenesis. As Associate Director of Process Development at Bioheart Inc., he developed and tech transferred media and process improvements for the isolation and expansion of autologous myoblasts for clinical evaluation of a cardiac repair cell therapy. In his next roles as VP of Operations and Product/Process Development at Histogenics Corporation, he established the regulatory, process development, manufacturing, quality, and clinical systems for GMP production and clinical evaluation of an autologous tissue engineered cartilage repair product. Eric joined Thermo Fisher Scientific as part of Invitrogen in 2008 where his experiences were leveraged to identify global opportunities for platform development and adoption of industry enabling tools. He currently focuses on building Global Strategic Alliances and expanding the Cell & Gene Therapy Business Unit at Thermo Fisher Scientific. Eric holds a BSc. in Biochemistry from McGill University and has authored nine patents and a number of publications in the fields of drug delivery, biomaterials, cell therapy, and tissue engineering.

Bryan Poltilove

Mr. Poltilove is an accomplished business leader in health care and life science industry.  Most recently, as Vice President and General Manager of Thermo Fisher’s Clinical Diagnostics Reagents business, Mr. Poltilove oversaw a $200M+ business and a fully integrated 400+ person organization.  Previously with the company, Mr. Poltilove launched a new business segment and led a corporate initiative focused in Cell and Gene Therapy.  In a prior role, he led a $350M portfolio of Cell Biology reagents and instrumentation.  Before joining Thermo Fisher, Mr. Poltilove served as the Director of Revenue Strategy & Operations for the Corporate Executive Board and held several roles with Johnson & Johnson.  He holds Bachelor’s degrees in Chemical Engineering and Economics from MIT as well as an MBA from Northwestern University’s Kellogg School of Management.